Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN – Get Rating) in a research report issued on Tuesday. The brokerage set a “hold” rating on the stock.

Shares of OGEN stock opened at $0.36 on Tuesday. The business’s 50-day moving average price is $0.37. Oragenics has a 12-month low of $0.30 and a 12-month high of $1.15. The company has a market capitalization of $42.23 million, a price-to-earnings ratio of -2.59 and a beta of 0.09.

About Oragenics (Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

See Also